Israeli company Voiceitt built an AI speech-recognition engine trained on atypical and dysarthric speech, letting people with severe speech impairments control Amazon Alexa and communicate independently; an NHS-funded Ace Centre trial (n=8) found genuinely mixed results.
8
Participants in the Ace Centre/NHS trial (3+ months use each)
Voiceitt, founded in Ramat Gan, Israel in 2012, develops an automatic speech-recognition engine trained specifically to understand atypical and dysarthric speech -- the non-standard speech patterns produced by conditions such as cerebral palsy, stroke, Parkinson's disease or Down syndrome. Its convolutional neural network analyses larger chunks of a user's acoustic signal holistically, and lets each user train a personalised model by repeating phrases until the system recognises them reliably. It is integrated into Amazon Alexa, whose Alexa Fund was an early investor, so a trained phrase can control smart-home devices.
Results
In a 2019 pilot at the Inglis House residential-care community in Philadelphia, participants with cerebral palsy and atypical speech reportedly controlled their environment within minutes of starting to train the app. A subsequent independently funded trial, run by the UK charity Ace Centre with support from the NHS Health Innovation Manchester Momentum Fund, had eight participants use Voiceitt for at least three months to assess whether it could improve communication, independence and quality of life. The write-up is honest about mixed results: some participants valued the Alexa smart-home control, while others found the requirement to pre-train and repeat fixed phrases limiting for spontaneous conversation.
Conclusions
No sample size beyond single digits, and no controlled comparison group, has been publicly reported, so Voiceitt's real-world effectiveness at scale remains only lightly evidenced -- a genuine, if modest, gain in independence for a severely underserved population, rather than a fully proven intervention.
Implementation
Indicative cost
Medium (€50k–€500k) — Backed by Amazon Alexa Fund investment; the independent trial was funded by the NHS Health Innovation Manchester Momentum Fund. No public unit-cost figures found.
Time to results
Long (> 3 years) — Founded 2012 in Ramat Gan, Israel; Inglis House pilot in 2019; Ace Centre/NHS trial ran 3+ months per participant.
Staffing & skills
AI/ML engineers at Voiceitt, Amazon Alexa Fund as investor/integration partner, Ace Centre clinical/assistive-technology specialists running the independent trial
Conditions for success
Personalised model training per user (repeating phrases until reliably recognised)
Integration into a mainstream smart-home platform (Alexa) rather than a bespoke standalone device
An independent clinical trial partner (Ace Centre/NHS) to assess real-world impact
Common failure modes
The requirement to pre-train and repeat fixed phrases limited spontaneous conversation for some participants
No sample size beyond single digits or controlled comparison group has been publicly reported
Where it fits
Governance type
private company plus NHS-funded clinical partnership
Scale
individual/household assistive-device use
Income level
high-income (Israel origin, UK NHS trial)
Commonly funded by
National / regional programmesOwn resources / municipal budget
Indicative funding routes for practices of this type — always check each programme's current calls and eligibility rules.
Do you run this practice?
Claim it —
verified implementers get a public contact pathway and can propose corrections.
Data sources
Where this practice's information was retrieved from, and when.
Serbian startup SignAvatar deployed 'TransportSign' at Belgrade's Central Railway Station, using AI to convert real-time public-transport announcements into sign-language avatar …